BioMarin Pharmaceutical Sees Major Investment Boost

Vinva Investment Management Ltd increases stake in biotech firm by over 200%

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Vinva Investment Management Ltd significantly increased its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) during the third quarter, according to a recent SEC filing. The firm added over 67,000 shares, boosting its stake in the biotechnology company by 216.5% to a total of 98,403 shares worth $5.3 million.

Why it matters

This substantial investment increase by Vinva Investment Management signals growing confidence in BioMarin's prospects among institutional investors. As a leading rare disease-focused biotech, BioMarin's pipeline and approved therapies make it an attractive long-term play in the sector.

The details

According to the filing, Vinva Investment Management now owns about 0.05% of BioMarin's outstanding shares after the major third-quarter increase in its position. Other notable institutional investors that have also added to their BioMarin stakes recently include AQR Capital Management, Viking Global Investors, and Dimensional Fund Advisors.

  • Vinva Investment Management increased its BioMarin holdings during the third quarter of 2025.

The players

Vinva Investment Management Ltd

An investment management firm that significantly boosted its stake in BioMarin Pharmaceutical.

BioMarin Pharmaceutical Inc.

A biopharmaceutical company specializing in therapies for rare genetic and metabolic diseases.

Got photos? Submit your photos here. ›

The takeaway

This investment increase by Vinva highlights the ongoing institutional interest in BioMarin's unique position in the rare disease drug market. As the company continues to advance its pipeline and commercialize new therapies, it remains an attractive long-term holding for specialized healthcare investors.